Are We Ready to Use Teriparatide to Treat Medication-Related Osteonecrosis of the Jaw in Clinical Practice?

J Clin Oncol. 2020 Sep 10;38(26):2949-2951. doi: 10.1200/JCO.20.01633. Epub 2020 Jul 13.

Authors

Carla I Ripamonti¹, Nicola Napoli^{2

3}

Affiliations

¹ Supportive Care in Cancer Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
² Unit of Endocrinology and Diabetes, Department of Medicine, Campus Bio-Medico, University of Rome, Rome, Italy.
³ Division of Bone and Mineral Diseases, Washington University in St. Louis, St. Louis, MO.

PMID: 32658629
DOI: 10.1200/JCO.20.01633

No abstract available

Publication types

Editorial
Comment

MeSH terms

Bisphosphonate-Associated Osteonecrosis of the Jaw* / drug therapy
Bone Density Conservation Agents* / adverse effects
Humans
Osteonecrosis* / chemically induced
Osteonecrosis* / drug therapy
Teriparatide / adverse effects

Substances

Bone Density Conservation Agents
Teriparatide